A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis (vol 5, pg 115, 2011)

被引：0

|

作者：

不详

机构：

来源：

JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷 / 01期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

收藏

页码：149 / 149

页数：1

相关论文

共 48 条

[41] Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial (vol 5, pg 877, 2017)
Holman, R. R.
Coleman, R. L.
Chan, J. C. N.
LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (05): : E5 - E5
[42] Evaluation of early administration of simvastatin in the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation (MoDUS): a randomised, double-blind, placebo-controlled trial (vol 5, pg 727, 2017)
Page, V. J.
Casarin, A.
Ely, E. W.
LANCET RESPIRATORY MEDICINE, 2018, 6 (04): : E15 - E15
[43] Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial (vol 21, pg 417, 2022)
Knight, Pestana E. M.
Amin, S.
Bahi-Buisson, N.
LANCET NEUROLOGY, 2022, 21 (07): : E7 - E7
[44] Evaluation of a probiotics, Bifidobacterium breve BBG-01, for enhancement of immunogenicity of an oral inactivated cholera vaccine and safety: A randomized, double-blind, placebo-controlled trial in Bangladeshi children under 5 years of age (vol 29, pg 1855, 2011)
Matsuda, F.
Chowdhury, M. I.
Saha, A.
Asahara, T.
Nomoto, K.
Tarique, A. A.
Ahmed, T.
Nishibuchi, M.
Cravioto, A.
Qadri, F.
VACCINE, 2011, 29 (35) : 6068 - 6068
[45] Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium, BB-12 and Lactobacillus rhamnosus, LGG in colorectal cancer patients: The Probio SK 006-Slovak cooperative oncology group trial
Mego, Michal
Danis, Radoslav
Chovanec, Jozef
Jurisova, Silvia
Bystricky, Branislav
Porsok, Stefan
Konkolovsky, Peter
Vaclav, Vladimir
Wagnerova, Maria
Stresko, Marian
Brezinova, Bibiana
Reckova, Maria
Sutekova, Dagmar
Pazderova, Natalia
Novisedlakova, Maria
Zomborska, Eva
Ciernikova, Sona
Svetlovska, Daniela
Drgona, Lubos
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[46] Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial (vol 1, pg e60, 2014)
Sierra-Madero, J. G.
Ellenberg, S. S.
Rassool, M. S.
LANCET HIV, 2015, 2 (10): : E416 - E416
[47] 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial (vol 13, pg 1050, 2013)
Bhattacharya, S. K.
Sur, D.
Ali, M.
LANCET INFECTIOUS DISEASES, 2013, 13 (12): : 1011 - 1011
[48] Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (vol 21, pg 242, 2020)
Hashimoto, H.
Abe, M.
Tokuyama, O.
LANCET ONCOLOGY, 2020, 21 (02): : E70 - E70

← 1 2 3 4 5 →